Self-reported cognitive decline in Japanese patients with breast cancer treated with endocrine therapy

被引:4
|
作者
Yamamoto, Sena [1 ]
Masutani, Eiko [2 ]
Arao, Harue [3 ]
机构
[1] Hakuaikai Sagara Hosp, Dept Nursing, 3-31 Matsubara Cho, Kagoshima, Kagoshima 8920833, Japan
[2] Osaka Univ, Grad Sch Med, Canc Educ & Res Ctr, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan
[3] Osaka Univ, Grad Sch Med, Div Hlth Sci, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan
关键词
Cognitive dysfunction; Long-term adverse effects; Cancer survivors; Quality of life; Patient-reported outcome measures; ADJUVANT CHEMOTHERAPY; IMPAIRMENT; PERFORMANCE; IMPACT; MANAGEMENT; SYMPTOMS; SEQUELAE; WOMEN;
D O I
10.1007/s12282-020-01062-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Despite contributing to the control of hormone receptor-positive breast cancer, a highly prevalent cancer type, endocrine therapy affects patients' cognitive function. We aimed to identify cognitive decline following the start of endocrine therapy using patient-reported measures and investigate factors associated with cognitive difficulties. Methods This cross-sectional survey used a self-administered, anonymous questionnaire. The participants were 876 patients with breast cancer who experienced subjective cognitive difficulties after starting endocrine therapy. Our sample was recruited from 11 patient advocacy groups, 5 clinics, and 2 hospitals in Japan. The questionnaire assessed subjective cognitive difficulties (30 items), psychological well-being, demographic and clinical information, and other subjective symptoms. Results Of 510 (58.2%) responses, we analyzed 405 (46.2%) questionnaires. Exploratory factor analysis identified three factors of cognitive difficulties: Factor 1, "difficulties in manipulating memory and language;" Factor 2, "difficulties in processing multiple pieces of information;" and Factor 3, "difficulties in maintaining attention and concentration." Factor 1 was the most common type, and it was significantly related to the treatment characteristics of endocrine therapy. Multivariate logistic regression analysis revealed that fewer household members, a history of breast surgery, more severe menopausal symptoms, and greater psychological distress were significantly associated with cognitive difficulties. As cognitive difficulties increased, the proportion of participants suspected to have psychological disorders increased significantly. Conclusions Patients treated with endocrine therapy for breast cancer experience intricately intertwined impairments in several domains of cognitive function. They have an increased risk of psychological disorders corresponding to the degree of subjective cognitive function.
引用
收藏
页码:670 / 682
页数:13
相关论文
共 50 条
  • [1] Self-reported cognitive decline in Japanese patients with breast cancer treated with endocrine therapy
    Sena Yamamoto
    Eiko Masutani
    Harue Arao
    [J]. Breast Cancer, 2020, 27 : 670 - 682
  • [2] Prevalence of self-reported cognitive dysfunction in breast cancer patients.
    Skirbe, Heidi
    Hohn, Gabriela
    Klein, Paula
    Juliano, Mary Ann
    Winell, Jeremy
    Rosenwald, Victoria
    Festa, Joanne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Prevalence of self-reported cognitive dysfunction in breast cancer patients.
    Skirbe, Heidi
    Hohn, Gabriela
    Klein, Paula
    Juliano, Mary Ann
    Winell, Jeremy
    Rosenwald, Victoria
    Boolbol, Susan K.
    Festa, Joanne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [4] Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer
    Shilling, Val
    Jenkins, Valerie
    [J]. EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2007, 11 (01) : 6 - 15
  • [5] Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer
    Shilling, V
    Jenkins, V
    [J]. JOURNAL OF WOMENS HEALTH, 2007, 16 (06) : 929 - 930
  • [6] Self-Reported Cognitive Impairment in Patients With Cancer
    Kohli, Sadhna
    Griggs, Jennifer J.
    Roscoe, Joseph A.
    Jean-Pierre, Pascal
    Bole, Christopher
    Mustian, Karen M.
    Hill, Renae
    Smith, Kelly
    Gross, Howard
    Morrow, Gary R.
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2007, 3 (02) : 54 - 59
  • [7] Real-world self-reported adherence to endocrine therapy in a large longitudinal cohort of breast cancer patients
    Ferzoco, Raina Mahajan
    Hallberg, Emily J.
    Vivek, Sithara
    Cogswell, Jodie A.
    Hinton, Jamie L.
    Marshman, Patricia J.
    Olswold, Curtis L.
    Goetz, Matthew P.
    Slager, Susan L.
    Olson, Janet E.
    Couch, Fergus J.
    Ruddy, Kathryn Jean
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Correspondence Between Objective and Self-reported Endocrine Therapy Adherence Among Women With Breast Cancer
    Bright, Emma E.
    Stanton, Annette L.
    [J]. ANNALS OF BEHAVIORAL MEDICINE, 2019, 53 (09) : 849 - 857
  • [9] CORRESPONDENCE BETWEEN OBJECTIVE AND SELF-REPORTED ENDOCRINE THERAPY ADHERENCE AMONG WOMEN WITH BREAST CANCER
    Bright, Emma E.
    Stanton, Annette L.
    [J]. ANNALS OF BEHAVIORAL MEDICINE, 2018, 52 : S238 - S238
  • [10] Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study
    Biglia, N.
    Bounous, V. E.
    Malabaila, A.
    Palmisano, D.
    Torta, D. M. E.
    D'Alonzo, M.
    Sismondi, P.
    Torta, R.
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2012, 21 (04) : 485 - 492